Emma Borrelli

Dr. Emma Borrelli

Siena University Hospital, Siena, Tuscany, Italy
Public Outpatient Clinic for Ozone Therapy, Siena Hospital

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2009 in Medicinal Research Reviews
Verified
Journal Article
Closed access
VBVelio Bocci
Velio Bocci
EBEmma Borrelli
Emma Borrelli
Valter TravagliValter Travagli
Valter Travagli
IZIacopo Zanardi
Iacopo Zanardi

1 March 1996 in Critical Care Medicine
Verified
Journal Article
Closed access
EBEmma Borrelli
Emma Borrelli
PRPascale Roux-Lombard
Pascale Roux-Lombard
Georges Emile GrauGeorges Emile Grau
Georges Emile Grau
EGEric Girardin
Eric Girardin
BRBara Ricou
Bara Ricou
PSPeter M. Suter
Peter M. Suter
The aims of this study were: a) to evaluate plasma concentrations of cytokines and their soluble receptors, as well as antioxidant substances in patients at high risk of developing multiple organ failure; b) to investigate early change: and c) to examine the possible prognostic value of these elements. Prospective analysis. Surgical intensive care unit (ICU) of a university hospital. sixteen patients at risk for multiple organ failure. Ten patients developed multiple organ failure and five of them died. Whereas tumor necrosis factor-alpha (TNF-alpha) plasma concentrations were only borderline higher in patients developing multiple organ failure, TNF-soluble receptors 55 and 75 were significantly increased during all ICU days compared with patients not going into organ failure. Interleukin-6 plasma concentrations were higher in patients developing multiple organ failure during the first 2 days after ICU admission. The antioxidant vitamin C was significantly decreased in patients going into multiple organ failure during all ICU days. Other biochemical markers of antioxidant activity, such as vitamin E, copper, and zinc plasma concentrations, did not differ between the two groups. Our data suggest that there is a marked increase in anti-TNF activity and a decrease of antioxidant defense in patients at risk of developing multiple organ failure. The predictive value of plasma concentrations of circulating TNF-soluble receptors and vitamin C in this type of patient needs further evaluation.

1 July 2003 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PGPierpaolo Giomarelli
Pierpaolo Giomarelli
SSSabino Scolletta
Sabino Scolletta
EBEmma Borrelli
Emma Borrelli
BBBonizella Biagioli
Bonizella Biagioli

4 February 2016 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
IZI. Zanardi
I. Zanardi
EBEmma Borrelli
Emma Borrelli
GVG. Valacchi
G. Valacchi
Valter TravagliValter Travagli
Valter Travagli
VBV. Bocci
V. Bocci
A comprehensive outline for understanding and recommending the therapeutic use of ozone in combination with established therapy in diseases characterized by a chronic oxidative stress is currently available. The view of the absolute ozone toxicity is incorrect, because it has been based either on lung or on studies performed in artificial environments that do not correspond to the real antioxidant capacity of body compartments. In fact, ozone exerts either a potent toxic activity or it can stimulate biological responses of vital importance, analogously to gases with prospective therapeutic value such as NO, CO, H2S, H2, as well as O2 itself. Such a crucial difference has increasingly become evident during the last decade. The purpose of this review is to explain the aspects still poorly understood, highlighting the divergent activity of ozone on the various biological districts. It will be clarified that such a dual effect does not depend only upon the final gas concentration, but also on the particular biological system where ozone acts. The real significance of ozone as adjuvant therapeutic treatment concerns severe chronic pathologies among which are cardiovascular diseases, chronic obstructive pulmonary diseases, multiple sclerosis, and the dry form of age-related macular degeneration. It is time for a full insertion of ozone therapy within pharmaceutical sciences, responding to all the requirements of quality, efficacy and safety, rather than as either an alternative or an esoteric approach.

1 May 2015 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
Valter TravagliValter Travagli
Valter Travagli
VBVelio Bocci
Velio Bocci
EBEmma Borrelli
Emma Borrelli
IZIacopo Zanardi
Iacopo Zanardi
Objective: The aim of this review is to elucidate the biochemical, molecular, immunological, and pharmaceutical mechanisms of action of ozone dissolved in biological fluids. Studies performed during the last two decades allow the drawing of a comprehensive framework for understanding and recommending the integration of ozone therapy for spinal pain. Methods: An in-depth screening of primary sources of information online – via SciFinder Scholar, Google Scholar, and Scopus databases as well as Embase, PubMed, and the Cochrane Database of Systemic Reviews – was performed. In this review, the most significant papers of the last 25 years are presented and their proposals critically evaluated, regardless of the bibliometric impact of the journals. Results: The efficacy of standard treatments combined with the unique capacity of ozone therapy to reactivate the innate antioxidant system is the key to correcting the oxidative stress typical of chronic inflammatory diseases. Pain pathways and control systems of algesic signals after ozone administration are described. Conclusion: This paper finds favors the full insertion of ozone therapy into pharmaceutical sciences, rather than as either an alternative or an esoteric approach.